# Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

> **NCT07070713** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer With Left-sided Primary Tumor
- Immunotherapy

## Interventions

- **DRUG:** FOLFOXIRI + QL1706 + Bevacizumab
- **DRUG:** FOLFOX+QL1706+Cetuximab

## Key facts

- **NCT ID:** NCT07070713
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-08-30
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2025-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07070713

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07070713, "Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT07070713. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*